Introduction
The theory that malignancies arise from a small subset of stem-cell-like cancer cells has received increasing attention during the past decade. These cells, referred to as cancer stem cells (CSCs) or cancer-initiating cells (CICs), have been identified in many malignancies and are hypothesized to form the clonogenic core of tumour tissues. 1 The origin of CSCs in human tumours is, however, not fully understood. Such cells could potentially originate from a more-differentiated cancer cell that acquires self-renewal properties, perhaps as a result of epithelial-to-mesenchymal transition (EMT). 2 Alternatively, CSCs might derive from a normal tissue stem cell that undergoes transformation as a result of oncogenic somatic mutations, under the influence of extrinsic microenvironmental factors. 3, 4 Although the co-occurrence of subpopulations of cancer cells with different tumorigenic properties within indivi dual tumours is no longer in question, 5 the CSC hypothesis remains controversial. This controversy arises as a consequence of the technical and logistical challenges in isolating and identifying CSCs from human solid tumours that contain heterogeneous cell populations, and the limited number of validated surrogate assays currently available to substantively confirm stem-cell-like properties. 6 These cells tend to comprise a small fraction of total tumour mass and are, therefore, difficult to unequivocally identify histologically. Moreover, tumour dissociation from normal tissues and subsequent flow cytometric analysis of tumour cells is not always possible with human biospecimens. Furthermore, markers that identify CSCs vary across different tumour types, and no clear-cut and clinically validated assay is currently available to quantify such cells in human tumours. 7 Nevertheless, some promising candidate biomarkers have been identified, 8 and surrogate assays for CSCs include the formation of secondary 'spheroids' in suspension culture, the generation of 3D organoids, and in vivo 'limiting dilution' tumorigenicity in immuno compromised mice. 9 Importantly, spheroid or organoid assays might be adaptable for clinical purposes; rigorous studies are needed to establish whether these assays can be used as surrogate biomarkers in a clinical setting. From a biological standpoint, the CSC hypothesis is supported by evidence from genetically engineered mouse models, which have elucidated the contribution of CSCs to the pool of proliferating tumour cells, as well as their potential as therapeutic targets in certain tumour types. [10] [11] [12] In experimental models, CSCs seem to be more resistant to chemotherapy and radiotherapy than 'differentiated' tumour cells. [13] [14] [15] Indeed, CSCs residing in fibrotic tissue and other microenvironmental niches can escape from the effects of conventional cytotoxic treatments. 16 Expansion of the remaining highly tumorigenic CSCs can resume after treatment cessation, driving tumour growth that presents as clinically relapsed or recurrent disease.
On the basis of these theories and observations, numerous researchers hypothesize that treatments targeting the CSC population could be more effective than existing therapies, and could dramatically transform treatment outcomes in oncology.
CSCs have been shown to have one or more aberrations in various signalling pathways; however, abnormal activity of pathways that control stem-cell self-renewal, and have important roles in embryonic development and differentiation, which include Notch, Hedgehog (HH), and Wnt, are probably most crucial to the tumorigenicity of CSCs. Increasing evidence demonstrates that these embryonic pathways can interact with other cellular signalling pathways, such as those involving NFκB, MAPK, PI3K, and EGF. Therefore, these developmental pathways might be important therapeutic targets for blockade of CSC self-renewal and p roliferation, and tumour progression. 17 Many new agents targeting the Notch, HH, and Wnt pathways have entered clinical trials since our previous Review article was published in this journal in 2011. 18 Thus, an update on the approval status and progress of these investigational agents towards routine clinical practice is warranted and is provided herein. In addition, we discuss strategies that hold the potential to further increase the effectiveness of such treatments, in particular, inhibition of the crosstalk between embryonic and other signalling pathways.
Targeting the Notch pathway
Notch signalling Notch signalling, similar to the Wnt and HH pathways, is a primordial, evolutionarily conserved cell-fatedetermination pathway that has great relevance to multiple aspects of cancer biology, from CSCs to angiogenesis to tumour immunity. 19 Notch signalling via transmembrane ligands and receptors is primarily involved in the communication between contiguous cells. 20, 21 That is, interaction between a transmembrane ligand on one cell and a transmembrane receptor on a neighbouring cell triggers a two-step proteo lytic cleavage of the receptor; the first cleavage is mediated by a disintegrin and metalloproteinase (ADAM) enzymes-either ADAM 10 or ADAM17, also known as tumour necrosis factor-α converting enzyme (TACE)-and the second by γ-secretase, which releases an intracellular fragment that can interact with nuclear factors to regulate target-gene expression ( Figure 1 ). The Notch signalling pathway is complex and multifaceted, reflecting its roles in diverse functional activities. The pathway comprises five canonical Notch ligands (Delta-like ligand 1 [DLL1], DLL3 and DLL4, and Jagged1 and Jagged2) and four Notch receptor paralogues (Notch1-4). 22 Different tumours and tumour subtypes can express different Notch receptors and ligands. Furthermore, post-translational modifications of Notch receptors can change their affinity for ligands and their intracellular half-lives. 19, 23 In addition, noncanonical Notch signalling pathways are beginning to be delineated, and some of these have relevance to cancer. [24] [25] [26] [27] [28] [29] Crosstalk with the Wnt and/or HH pathways might also determine the overall effect of Notch signalling, adding an additional layer of complexity. 30 The significance of the diversity in Notch signalling outputs in the context of clinical oncology is twofold: on the one hand, targeting Notch signalling has the potential to simultaneously affect multiple cell types within a tumour, from CSCs to immune cells, vascular endothelial cells and tumour cells; on the other hand, the successful development of agents targeting the Notch pathway will require a mechanistic understanding of the role of Notch signalling in specific cancers, and ideally, the development and use of mechanism-based combination regimens. The main issues in the development of agents targeting Notch signalling in oncology include: choice of the most appropriate inhibitor for each patient; identification of pharmacodynamic biomarkers as surrogate end points for pathway inhibition; selection of mechanism-based combination regimens; and patient stratification according to recognized efficacy biomarkers.
Investigational Notch-signalling inhibitors γ-secretase inhibitors At present, several classes of Notch-pathway inhibitors are in clinical development, with significant differences in the targets, mechanism of action, and drug class (Table 1) . A major class of agents targeting the Notch pathway is the γ-secretase inhibitors (GSIs), which prevent the final proteolytic cleavage of Notch receptors that releases the active intracellular fragment ( Figure 1) ; GSI were the first class of Notch inhibitors to reach clinical development in onco logy. 31 These agents have been shown to have strong antineoplastic activity in numerous preclinical models, especially in combination with either chemotherapy or targeted agents. For example, in a mouse model of HER2-positive breast cancer, GSIs in combination with trastuzumab achieved complete cures and abrogated recurrence. 32 GSIs also have demonstrated anti-CSC activity in ex vivo patient-derived tumour specimens and breastcancer-derived secondary mammospheres. [33] [34] [35] [36] Clinical benefit from GSIs has also been observed; for example, the oral GSI PF-0308414 was found to have promising clinical activity in a phase I dose-finding study in patients with advanced-stage solid tumours. 37 Among a total of 64 patients who received PF-0308414, one patient with advanced thyroid cancer had a complete response, and five of seven patients with desmoid tumours (71.4%) achieved a partial response. 37 In humans, the dose-limiting toxicity of GSIs is secretory diarrhoea. [38] [39] [40] Preclinical studies have shown that this effect is due to goblet-cell metaplasia of the smallintestinal epithelium-a target-mediated effect resulting from inhibition of Notch1 and Notch2, which abolishes the proliferative potential of crypt progenitors and causes them to differentiate into post-mitotic goblet cells. 41 Patients have also been observed to develop a cutaneous rash after treatment with GSIs in several phase I clinical trials. 37, 42 This adverse event might be attributable to production of thymic stromal lymphopoietin (TSLP), a cytokine that mediates the release of T-cell-attracting chemokines and results in the development of atopic dermatitis in the skin: TSLP is expressed in the epidermis upon loss of Notch function in mice. 43 Despite the adverse effects associated with production of this cytokine, TSLP1 might nevertheless be a useful biomarker of systemic Notch-pathway inhibition. GSIs also have the potential to modulate T-cell responses via other mechanisms, and this activity has been used therapeutically in experimental models of graft-versus-host disease (GVHD) and aplastic anaemia. 44 To limit toxicity, most investigators use intermittent GSI administration regimens, from 3-dayson-4-days-off to once weekly, depending on the pharmacokinetics of individual agents. In addition, combining GSIs with glucocorticoids 45 or antioestrogen agents 46 decreased intestinal toxicity in animal models, and intermittent administration of two different GSIs in combination with tamoxifen, letrozole or exemestane was well tolerated in pilot clinical studies. 47, 48 Thus, the advantages of GSIs include generally favourable tissue penetration, low cost, ease of administration and potential pan-Notch inhibitory activity. 19, 23 Potential disadvantages are systemic toxicity and off-target effects, as γ-secretase has >90 substrates in addition to the Notch receptors; GSIs potentially inhibit the cleavage of all substrates, which might contribute to their toxicity and/or effectiveness in ways that are not currently understood. Importantly, whether intermittent administration of GSIs-which largely spares intestinal epithelial stem cells and, therefore, reduces toxicity-has suboptimal therapeutic effects on CSCs and tumours remains unclear.
Different chemical classes of GSIs are not pharmacologically equivalent and are not interchangeable. Indeed, the pharmacokinetics, activity against different Notch paralogues, and off-target effects of different GSIs vary significantly. For example, RO4929097-the agent tested in most of the GSI clinical trials to date-induces its own hepatic metabolism via cytochrome P450 family 3 subfamily A polypeptide 4 (CYP3A4), which limits the achievable area under the curve (AUC) of drug exposure (that is, bioavailability). 49 One agent in development, BMS-906024, is an intravenous compound, whereas other GSIs are formulated for oral administration (Table 1) . Furthermore, evidence indicates that cleavage of Notch4 is inhibited by some GSIs, but not by others. 50 At present, whether a specific chemical class of GSI is preferable in terms of safety and/or efficacy is not clear, and the results of ongoing clinical and p reclinical studies will provide valuable i nformation on this topic.
Anti-DLL4 antibodies
Targeting DLL4 with monoclonal antibodies (mAbs) is another strategy to block Notch signalling that is being developed in the clinic (Figure 1 ). Productive tumour angiogenesis requires cooperation between VEGF-A, which induces proliferation of endothelial 'tip' cells and expression of DLL4 in 'stalk' cells. 51 In this context, DLL4 inhibits endothelial proliferation and promotes branching morphogenesis, and the balance between proliferation and In a recent clinical trial, the anti-DLL4 mAb enoticumab (also known as REGN421 and SAR153192) had a reasonable safety profile and demonstrated preliminary efficacy signals. 52 The most-common severe (grades 3-4) adverse events were fatigue, headache, hypertension and nausea; 52 reversible severe adverse events included increased levels of the cardiac proteins natriuretic peptides B and troponin I, and right and left ventricular dysfunctions. 52 Two partial responses and 16 stable disease responses (three prolonged for >6 months) were observed among the 53 patients with ovarian cancer and other solid tumours who were treated with enoticumab. 52 However, caution is needed as, in animal models, chronic treatment with anti-DLL4 mAbs caused haemangiomas due to un opposed VEGF-mediated endothelial proliferative activity, and liver t oxicity due to sinusoidal endothelial toxicity. 53 Interestingly, high expression of the Notch ligand DLL4 has been shown to predict resistance to sunitinib-targets of which include VEGF receptors-in metastatic renal cell carcinoma (mRCC). 54 Thus, whether DLL4 and VEGF inhibitors can be safely combined in the treatment of cancer is of interest, as this approach might deliver superior antiangiogenic activity compared with either class of agent alone. A phase I trial (NCT01131234) 55 is examining the combination of the GSI RO4929097 and the VEGF-targeting agent cediranib in patients with advanced-stage solid tumours. Preliminary data from this trial suggest that the combination was well tolerated at the dose levels used, with diarrhoea, hypertension, fatigue and nausea representing the most-common treatment-related adverse events. 56 Other approaches to targeting Notch signalling Other Notch inhibitors in the clinical pipeline include mAbs targeting various Notch receptors, mAbs to the γ-secretase complex component nicastrin, and soluble decoy Notch receptors that interfere with ligand-receptor interactions (Table 1; Figure 1) . 19 A recent addition to this drug superfamily is a novel class of disease-specific protease-activated mAbs (termed 'probodies') to Notch ligands; currently an anti-Jagged1/2 probody is in preclinical development. 57 The context-specific activation of these agents against Notch targets offers the possibility of tumour-selective inhibition of Notch signalling, potentially improving the therapeutic window and overcoming the need for intermittent inhibition.
Notch1 has been shown to act as a tumour suppressor in neuroendocrine tumours, and inhibitors of histone deacetylases (HDACs), which are enzymes that can protect cells from apoptosis and that might therefore reduce the clinical activity of anticancer therapies, have been demonstrated to upregulate Notch1 expression. 58 Thus, a phase II trial in patients with neuroendocrine tumours (NCT00985946) tested the hypothesis that, by relieving the antiapoptotic effects of HDACs, HDAC inhibition could suppress tumour growth and induce tumour-cell June 6, 2014 ; default status is recruiting or active but not recruiting. Abbreviations: aka, also known as; CNS, central nervous system; ER, oestrogen receptor; FOLFIRI, 5-fluorouracil plus folinic acid and irinotecan; FOLFOX6, 5-fluorouracil plus folinic acid and oxaliplatin regimen for six cycles; GSI, γ-secretase inhibitor; HSCT, haematopoietic stem-cell transplantation; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; T-ALL, T-cell acute lymphoblastic leukaemia; TNBC, triple-negative breast cancer; WBRT, whole-brain radiotherapy.
apoptosis via upregulation of Notch1; 59 however, this study was stopped early as no clinical responses were observed. Another trial studied the effects of the same HDAC inhibitor in metastatic medullary or radioiodine-resistant differentiated thyroid cancers (NCT01013597). 60 This study has completed accrual, but results have not been published. Additionally, natural phytochemicals, such as resveratrol, have been reported to inhibit Notch signalling. 19 At least one clinical trial is currently investigating possible inhibitory effects of resveratrol on Notch signalling in gastrointestinal n euroendocrine tumours.
61
Further progress in the development of Notch inhibitors for CSC targeting will require an unbiased comparison of the many pharmacological strategies developed thus far, and possibly the development of next-generation agents. The agents used in the greatest number of early clinical trials to date are not necessarily the most promising ones, for the reasons discussed. Moreover, developmental pathways, including Notch, function in concert with otherpathways to dictate cell fate, rather than as a simple on-off switch. Ideally, the most scientifically sound approach to targeting this pathway would leverage tumour-specific or target-specific agents used in mechanism-based combinations, in tumour types in which the roles of particular Notch family members in CSC can be documented. Indirect strategies targeting amenable nodes in Notch signalling other than ligands or receptors are also an a ttractive possibility.
Biomarkers of Notch signalling

Predictive biomarkers
Patient stratification is a key issue for the clinical development of Notch inhibitors. Ideally, biomarkers indicative of Notch-pathway activity with functional relevance in a specific tumour would guide patient stratification (that is, biomarkers predictive of response), but attempts to identify candidates for Notch-targeted therapy based on this premise have not proved straightforward. Expression levels of canonical Notch target genes is correlated with Notch-activating mutations and is a good indicator of Notch-pathway activity in T-cell acute lymphoblastic leukaemia (T-ALL); 62, 63 however, this relationship does necessarily imply that expression of the same target genes is indicative of Notch activity in all malignancies owing to a number of factors-not least the notorious contextdependence of Notch signalling cascade and outcomes, which are dynamic and influenced by other chromatin cofactors. 64 Moreover, expression of different Notch paralogues varies across tumours. 23 Although, in theory, all Notch receptors signal through the same canonical pathway, their target genes can differ. For example, in preclinical models of endocrine-resistant breast cancer, both Notch1 and Notch4 are oncogenic; 46 however, they modulate vastly different and minimally overlapping sets of target genes, 46 which has complicated biomarker identification. Detection of nuclear accumulation of the cleaved Notch1 intracellular domain is a good predictor of canonical Notch1 activity. 65 However, reliable anti bodies that specifically detect cleaved Notch receptor peptides in clinical samples are presently limited to Notch1. 65 In addition, consideration of the importance of emerging non canonical Notch signalling pathways, through which Notch can function independently of target-gene transcription mediated by conventional ligand binding, 66 is required. Gain-of-function mutations in Notch receptors or Notch-pathway regulatory proteins have been detected in more than 50% of T-ALL cases and in a much smaller proportion of solid tumours. 23 In many cases, these mutations produce truncated proteins that lack functional extra cellular domains and are, therefore, ligand-independent. However, whether these mutations can serve as efficacy biomarkers for monotherapy with Notch-pathway inhibitors remains unclear in light of the lack of clinical activity observed in patients with Notch1 mutations. 65 In the future, investigators who plan to develop Notch inhibitors for a specific indication should simultaneously investigate biomarker expression, especially those indicative of the pathway activity, such as Notch cleavage fragments and potential Notch target genes that correlate with sensitivity to inhibition of this pathway in relevant preclinical models. At present, expression of the cleaved Notch1 intracellular domain and Notch target gene HES4 represent the most-promising predictive biomarkers of response to Notch-targeted therapies in triple-negative breast cancer (TNBC) and salivary adenoid cystic carcinoma. 67 
Biomarkers of target modulation
The pharmacodynamic biomarkers that are tightly linked to Notch-pathway inhibition are also underdeveloped, especially for solid tumours. 68 Of note, monotherapy Notch-pathway inhibition will not necessarily result in radiologically detectable tumour-volume effects in all indications, as they predominantly target the rare clonogenic CSC population. Nevertheless, such effects have been seen with some GSIs in patients with central nervous system (CNS) tumours, 42 and for metastatic oestrogen receptor (ER)-positive breast cancers after treatment with GSI in combination with exemestane. 47 Ex vivo spheroid ('tumoursphere') formation assays from patient-derived samples might provide in direct information on the effects of treatment on CSCs, especial ly in pre-surgical (neoadjuvant) studies in which post-treatment tumour samples are likely to be available for analysis. Tumoursphere-formation assays have been used especially in studies of neurological malignancies and breast cancer.
69,70 Although a clinically standardized assay is not available, promising approaches have been developed, such as the 'sphere limiting dilution assay' , which can enable more-precise quantification compared with non-limiting dilution assay. 71 Molecular biomarkers of systemic Notch inhibition (such as inhibition of HES1 expression in hair follicles, or TSLP production) might have utility as biomarkers of target engagement, but do not necessarily prove or reflect Notch inhibition in tumour tissue. Neoadjuvant studies or studies including post-treatment biopsies will be necessary to guide our understanding of how molecular biomarkers correlate with target engagement, as well as clinical response to and effectiveness of Notch-pathway inhibition.
Combination regimens
Mechanism-based drug combinations incorporating Notch-pathway inhibitors deserve thorough investigation. Such approaches will require that all cross-signalling networks in CSCs are considered in a context-dependent manner and specific disease settings. Notch signalling can interface with and influence a large number of cancerrelevant pathways-controlling EMT, DNA repair, the cell cycle, and apoptosis. 2, 72 For example, cooperation between β-catenin (Wnt) and Notch signalling has been documented in colorectal cancer 73, 74 and myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML); 75 Notch and transforming growth factor-β (TGF-β) are known to have cooperative tumorigenic effects in RCC 76 and TNBC. 77 As described, Notch-signalling inhibitors, similar to inhibitors that target other developmental pathways relevant to CSCs, will not necessarily produce singleagent, short-term tumour volume responses in early phase clinical trials, unless they have considerable cytostatic, cytotoxic or antiangiogenic activity separate from their effect on CSCs. Nevertheless, these agents show promise with regards to survival, through prevention of disease recurrence or relapse that might be mediated by CSCs that persist after exposure to other therapies. An instructive example is provided by the GSI MRK003, a compound only used in preclinical models to date. This agent had a marked single-agent tumour-volume effect in models of endocrine-resistant breast cancer. 46 By contrast, in a mouse xenograft model of HER2-positive breast cancer, the same agent had no single-agent tumour-volume effect, nor did it increase the remarkable tumour-volume effect of trastuzumab.
32 Nonetheless, the GSI-trastuzumab combination completely abolished tumour recurrence, presumably by interfering with CSCs, whereas treatment with trastuzumab alone resulted in a 50% recurrence rate.
32
Similar results were seen in the same study with a chemically different GSI: LY411575.
32 Thus, as with other targeted agents, it is possible that Notch-pathway inhibitors will show optimal efficacy in the context of combination regimens. These investigational agents should, therefore, be tested in combinations with established drugs (and if warranted, in combinations with other novel agents), on the basis of the available preclinical mechanistic rationale. Examples include combinations of Notch-pathway inhibitors with endocrine therapy in ER-positive breast cancer, 46, 47, 78 with HER2 inhibitors in HER2-amplified breast cancer, 32,79 and with taxanes and MET inhibitors in TNBC. 80, 81 In fact, combinations of inhibitors of Notch signalling with endocrine therapy have been translated to the clinic with promising results in terms of safety and preliminary efficacy signals. 55, 62 For instance, in a phase Ib dose-escalation study, the oral compound RO4929097 in combination with exemestane showed one partial response and six cases of stable disease among 15 patients with recurrent ER-positive breast cancer. 47 In addition, phase I/II trials with GSIs and chemotherapy or targeted therapies are being conducted. For example, a phase I trial of combined RO4929097 and cediranib treatment reported one partial response and 11 cases of stable disease in 20 patients with advanced-stage solid tumours. 56 Current clinical relevance Despite accumulating evidence supporting the importance of Notch signalling in the regulation of CSCs in numerous malignancies, clinical experience with Notchpathway inhibitors remains relatively limited. Most of the completed clinical trials have been performed with one particular GSI, RO4929097, which had a potential pharma cokinetic liability-auto-induction of RO4929097 metabolism that resulted in marked reduction of steadystate drug levels. 82 Several other structurally and pharmacologically distinct GSIs are being investigated clinically, and a number of biological agents directed at specific components of the Notch pathway have recently entered preclinical and clinical testing ( Table 1) . It remains to be determined which of these classes of agents hold the most promise in the treatment of cancer. Some Notchpathway components (such as Notch4) are not targets of current biological agents, and might be one of the resistance mechanisms to some GSIs; further research on the effects of inhibiting these components is needed. In addition, novel Notch mutations and biomarkers of Notch activity that predict sensitivity to GSIs in some tumours have only recently been discovered, and further efforts in this area are required. At this time, the most-promising avenue for therapeutic targeting of this pathway seems to be mechanism-based, biomarker-driven combinations, but such approaches also need further development.
Targeting the Hedgehog pathway
Hedgehog signalling
The HH signalling pathway is implicated in tissuepatterning during embryonic development and the repair of normal tissues, and epithelial-to-mesenchymal transition. 83 Binding of HH ligands-Sonic hedgehog (SHH), Indian hedgehog (IHH), or Desert hedgehog (DHH)-relieves the inhibitory effect of their Patched (PTCH) transmembrane receptors on Smoothened (SMO), which is also located in the cell membrane ( Figure 2 ). 84 Subsequently, the signalling cascade initiated by SMO leads to activation and nuclear localization of GLI transcription factors, which drive expression of HH target genes; most of the target genes are involved in proliferation, survival, and angiogenesis. 85 This cascade represents a novel target for cancer therapy, as aberrations in the HH pathway contribute to tumorigenesis and tumour growth through several mechanisms. These mechanisms include mutations in the key members of the pathway, such as loss-of-function mutations in PTCH1 gene encoding Patched 1 and gain-of-function mutation in the SMO gene, that result in ligand-independent activation of the HH pathway, as well as ligand-dependent signalling by either autocrine or paracrine routes. 85 Mutation-driven mechanisms of HH-pathway activation have been demonstrated in basal-cell carcinoma (BCC) of the skin, medulloblastoma, and rarely rhabdomyo sarcoma. 86 Indeed, PTCH1 mutations are associ ated with HH-pathway hyperactivation in >90% of BCCs and 30% of adult medulloblastomas. 87 Furthermore, patients with Gorlin syndrome (basal-cell nevus syndrome), an autosomal dominant condition associated with germline loss of one copy of the PTCH1 gene, have a predisposition to develop ment of BCC and medulloblastoma. 88 The aetio logy of rhabdomyosarcomas, although thought to o riginate by a similar mechanism, is controversial. 89 Similarly to the Notch cascade, HH signalling can involve canonical and noncanonical pathways. Canonical signalling follows the PTCH1-SMO-GLI axis (Figure 2 ), whereas noncanonical pathways can be SMO-independent. 85 The noncanonical signals are largely attributed to various tumour-associated signalling pathways integrating with HH signalling, in part by influencing the activity of GLI transcription factors. 85 As such, HH-pathway activation can be triggered by many other intracellular signals, including those mediated by TGF-β, KRAS-MAPK/ERK, PI3K-AKT, IGF, TNF-α induced mTOR/S6K1 activation, and inactivation of hSNF5 (a regulator of chromatin remodelling, also known as SMARCB1). [90] [91] [92] [93] [94] Determining the role of these pathways in cancer, and the molecular crosstalk between them, is an important consideration for the development of HH-targeting agents, and the appropriate selection of a class of inhibitors for therapeutic intervention. 95, 96 Vismodegib is a direct, cyclopaminecompetitive antagonist of SMO. A recent analysis of pooled data from patients with advanced-stage BCC included in the pivotal phase II that led to FDA approval and phase I studies indicates that a median overall survival duration of 2.8 years was achieved in patients with metastatic BCC who received vismodegib monotherapy, compared with 2.0 years estimated from the literature for standard treatments. 97 These data indicate that the SMO inhibitor might improve overall survival in patients with BCC and distant metastases. Currently, vismodegib is being evaluated in the neoadjuvant setting for locally advanced BCC, 98 and in various settings in other advanced malignancies.
Clinical drug development
A survival benefit for vismodegib monotherapy might be expected in BCC, considering that around 95% of such tumours are associated with activation of the HH pathway. Vismodegib monotherapy has also been explored in glioblastoma, in particular, in a unique pilot phase II study in patients with relapsed or refractory glioblastoma who might benefit from debulking surgery. 99 A total of 40 patients were randomly assigned to neoadjuvant t reatment with daily vismodegib for 1 week versus no treatment, and all patients subsequently underwent surgery and received adjuvant vismodegib until disease progression. 99 Although survival differences were not observed, compared with adjuvant treatment only, neoadjuvant and adjuvant vismodegib treatment did substantially decrease CSC content and/or viability in tumour tissues, based on reduced capacity of tumour-derived CD133 + cells to form neurospheres. 99 However, in contrast to studies in BCC, this study did not show compelling clinical efficacy of vismodegib as a single agent, because the median PFS and overall survival durations of the patients were comparable to the control groups of historical studies: 1.8 months and 8.3 months, respectively. unselected patient populations have been disappointing. For example, three randomized, phase II studies investigating the addition of vismodegib to a chemotherapy backbone in patients with gastric or gastroesophageal junction tumours (n = 124), pancreatic cancer (n = 106) and extensive-stage small-cell lung cancer (ES-SCLC; n = 155) showed no statistically significant improvement in PFS or overall survival. [100] [101] [102] In addition, a phase II single-arm study in which patients with pancreatic cancer were treated with gemcitabine, nab-paclitaxel and vismodegib showed PFS of 5.5 months and overall survival of 10 months; 103 however, a PFS duration of 5.5 months is numerically similar to that observed in a phase III study of gemcitabine and nab-paclitaxel, 104 suggest ing limited or minimal contribution of vis modefib to the treatment effect. Similarly, in a phase II, randomized, placebocontrolled clinical trial in 199 patients with previously untreated metastatic colorectal cancer (mCRC), 105 the addition of vismodegib to combination treatment with FOLFOX (5-fluorouracil , folinic acid and oxaliplatin) or FOLFIRI (5-FU, folinic acid and irinotecan) chemo therapy plus bevacizumab did not increase PFS or the overall response rate (ORR). This trial failed to validate the hypothesis that inhibition of HH-signalling networks between tumour cells and stromal cells might have clinical antitumour activity in combination with standard-of-care chemotherapy. 105 In addition, expression of HH ligands, or SMO or PTCH1 mRNA in tumour tissue did not predict clinical benefit in exploratory analyses. 105 Vismodegib has also been investigated as a potential maintenance therapy. In a phase II, randomized, placebocontrolled trial, 106 among 104 patients with ovarian cancer who were in second or third complete remission after chemo therapy, maintenance therapy with this agent did not result in a statistically significant improvement in PFS. Furthermore, a higher incidence of treatment discontinuation occurred in the vismodegib group versus the placebo cohort. 106 The frequency of HH-ligand expression was lower than expected in archival tumour tissue from the study participants, being detected in only 13.5% of samples; 106 thus, correlation between tumour expression of HH ligands and clinical benefit was problematic. Moreover, exploratory analyses of the relationship between PFS and expression levels of SMO or GLI1 also did not suggest any correlation. 106 The negative trial results of targeting the HH pathways in unselected patients are not limited to studies of vismodegib. Three randomized phase II trials of the SMO inhibitor saridegib (also known as IPI-926) in pancreatic cancer, chondrosarcoma and myelofibrosis were stopped early due to lack of clinical activity. 107, 108 Thus, several other trials are evaluating rational treatment with SMO inhibitors in patients with tumours in which CSC selfreplication is driven by autocrine secretion of HH ligands (Table 2) . For example, a phase III, multicentre, openlabel, randomized study is comparing the efficacy and safety of oral sonidegib (also known as erismodegib and LDE225) versus temozolomide in the treatment of patients with relapsed HH-pathway-activated medulloblastoma (NCT01708174). 109 In a randomized, double-blind phase II trial of sonidegib, a high disease control rate, including complete, partial, and stable-disease responses, was observed in patients with locally advanced and metastatic BCC at both 200 mg and 800 mg daily dose levels, with 200 mg having a more favourable risk-benefit profile. 110 Considering the characteristic activation of HH signalling in this cancer type, these data lend support to the activity of sonidegib in other cancers driven by this pathway. Of note, HH signalling is implicated in tumorigenesis and progression of SCLC, and in one study, therapeutic activity with sonidegib plus etoposide and cisplatin was observed in 50% (7/14) of patients with ES-SCLC; 111 however, a randomized trial will be necessary to evaluate the effect of sonidegib in this combination therapy approach. Of note, a phase II, randomized trial investigating cisplatin and etoposide therapy with and without vismodegib in patients with SCLC found no statistically significant improvement in PFS or overall survival with addition of vismodegib. 100 The HH-pathway downstream transcription factor GLI1 has been found to have an important role in resistance to therapy in leukaemia cells by inducing expression of UDP glucuronosyltransferase enzymes that glucuronidate and inactivate drugs used to treat this disease, such as ribavirin and cytarabine. 112 Subsequently, several clinical trials of agents targeting SMO have been initiated in patients with relapsed or refractory high-risk AML (NCT02073838, NCT01880437 and NCT02129101).
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Biomarkers of HH signalling Predictive biomarkers to guide patient selection might be critical for the successful clinical evaluation of HH-pathway inhibitors against cancer types other than BCC or medulloblastomas that are specifically associated with a high frequency of driver mutations in this pathway. Even in medulloblastoma, the frequency of identification of actionable genetic mutations ranges from only 15-30%, depending on the age distribution. 86, 87 These data underscore the need for identification of biomarkers to design rational combination therapies according to the output of the active signalling pathways identified. 87 Sequencing of PTCH1 and SMO can be challenging, as whole-locus sequencing is required, especially for PTCH1-owing to the lack of a mutational hot-spot in this tumour suppressor gene. Presently, mRNA expression signatures are used as biomarkers of the activity of the HH pathway, as no antibodies specific for HH targetgene products that work reliably in immunohisto chemistry (IHC) assays are available. 116 However, Ellison et al. 117 published an elegant paper describing the classification of medulloblastomas into SHH, Wnt, or non-SHH/Wnt subtypes based on IHC with antibodies targeting four different proteins. In addition, Shou and colleagues 118 have developed a proprietary reverse-transcription PCR (RT-PCR)-based HH-signature assay as a patient pre-selection tool for HH-inhibition therapy; this 5-gene HH signature was selected from 32 differentially expressed candidate genes associated with SHH-subgroup classification of medulloblastoma, and includes the following genes: GLI1; SHROOM2; SPHK1; PDLIM3; and OTX2. 118 A predictive model was generated, and the predictive value of this assay was analysed using pretreatment medulloblastoma samples derived from 50 patients enrolled in three phase I studies of sonidegib. 118 Of these patients, 41 were predicted to have HH-inactive tumours. These 41 patients all had either disease progression, stable disease, or were not evaluable for tumour response. 118 Among the remaining nine patients, who had tumours with HH activation, six had objective responses-three complete responses and three partial responses. 118 Nevertheless, the value of this assay for predicting response to HH-pathway inhibition in patients with recurrent medulloblastoma is under evaluation in an ongoing phase III trial of sonidegib. Developing assays to evaluate expression of effectors of the HH pathway, such as GLI1 and GLI2, might be important to identify patients with tumours that are likely to respond to inhibitors of HH signalling-particularly for tumours other than BCC or SHH-subtype medulloblastomas; consequently, d evelopment of specific antibodies is warranted.
Resistance mechanisms
To date, clinical efficacy has not been demonstrated in trials of SMO inhibitors, except in patients with tumours driven by mutations in components of the HH-signalling cascade, such as SMO and PTCH1. 119 Possible reasons for primary resistance to HH-inhibitor monotherapy and the lack of additional efficacy or benefit in combination with chemotherapy, compared with the outcomes of chemotherapy alone, include insufficient drug concentrations in the stroma. This resistance mechanism has been discussed in detail by Graham and colleagues, 120 who described an unusual pharmacokinetic profile for vismodegib, owing to high-affinity, reversible binding to plasma proteins, solubility-limited absorption, and slow metabolic elimination. Compensatory upregulation of other signalling represents another potential resistance mechanism; for example, primary resistance to SMO inhibitors can be due to noncanonical activation of GLI transcription factors through pathways that bypass SMO and, therefore, the effects of SMO inhibitors. 121 A mutation in SMO (D473H) in a tumour that progressed after 3 months of vismodegib treatment was detected in a patient with medulloblastoma who harboured a PTCH1 mutation in both primary and metastatic lesion biopsies taken before therapy. 122 The SMO D473H mutation was only present after tumour progression and caused disruption of the vismodegib-binding site on SMO, and was, therefore, considered as the cause of acquired resistance. 122 This type of mutation was also found in a mouse model of vismodegib-resistant medulloblastoma. 122 Other mechanisms of acquired resistance, such as amplification of GLI2 or cyclin D1, noncanonical GLI activation, and noncanonical GLI-independent signalling downstream of SMO have also been described in preclinical models, including both xenograft and genetically engineered mouse models. 121, 123, 124 These models successfully demonstrated the new hypotheses that parallel, interacting, and compensatory pathways are intertwined with the HH signalling pathway and can be upregulated in cancer. However, these preclinical models aimed at discovering new scientific hypotheses are not necessarily the best model to predict clinical outcome. Thus, to maximize predictive capability, preclinical experi ments should be carefully designed and results should be evaluated statistically, before considering clinical trials to test the efficacy and toxicity of novel combinations of therapies. 125 At present, the molecules and pathways that are implicated in resistance to SMO inhibitors include the PI3K pathway, small GTPases, Src-family kinases and arachidonate metabolites. 126 Interestingly, in preclinical medulloblastoma models, resistance to SMO inhibitors could be prevented through combination therapy with SMO and PI3K-AKT inhibitors. 123 Furthermore, vismodegib was not effective in oesophageal cancer cells with overactivation of mTOR-S6K1 signalling (a downstream target of PI3K-AKT), owing to SMO-independent, mTOR/S6K1-mediated GLI1 activation; combination treatment with the mTOR inhibitor everolimus and vismodegib showed better inhibitory effects on the growth of these cells in a xenograft model than either drug alone. 94 Other preclinical studies suggest that this principle could be applied to other cancers. For example, in a model of tamoxifen-resistant breast cancer, the PI3K inhibitor LY294002 decreased SMO and GLI1 protein levels by 50%, suggesting a possible ration ale for combined therapy to overcome endocrine resistance through targeting residual HH activity with SMO inhibitors. 121 In addition, simultaneous activation of HH and PI3K signalling was seen in a PTENdeficient glioblastoma model, and combined inhibition of the PI3K/mTOR and HH pathways induced synthetic lethality in PTEN-deficient cells in vitro and in vivo. 127 On the basis of these models, two phase I combination therapy trials are currently investigating simultaneous targeting of the HH and PI3K-mTOR pathways with vismodegib plus sirolimus, 128 or sonidegib plus buparlisib (also known as BKM120; Table 2 ).
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Whether resistance to one SMO inhibitor can be overcome by another SMO inhibitor remains unclear. Most SMO inhibitors currently in clinical trials compete with cyclopamine binding to SMO, and therefore all presumably target the same-or an overlapping-binding site. 85, 130 A possible exception is itraconazole, an antifungal agent with pleiotropic effects including direct inhibition of SMO by binding at a site distinct from the one targeted by vismodegib, thereby preventing SMO accumulation in cilia, an event that is necessary for activation of HH signalling. 131 Thus, itraconazole might be effective as a second-line therapy, because it inhibits SMO with less potency than vismodegib and is associated with a different spectrum of adverse events than other drugs in this class, including vismodegib. 130 However, whether itraconazole can overcome resistance to vismodegib mediated by SMO missense mutations remains to be established; in one study itraconazole did not induce a statistically significant decrease in GLI1-mRNA expression or tumour shrinkage in patients previously treated with vismodegib. 130 Nevertheless, itraconazole could potentially serve as a lead compound for the d evelopment of more-potent s econd-generation SMO inhibitors.
An alternate strategy to overcome resistance to SMO inhibitors is to inhibit a different pathway target. Strong evidence of SMO-independent GLI activation suggests the development of direct GLI inhibitors could be warranted. Arsenic, another well-known pleiotropic agent, is a 'direct' inhibitor of GLI transcription factors and inhibits HH activity even downstream of vismodegib-resistant, mutant SMO. 132 A combination of arsenic and itraconazole was effective in vitro and in vivo in models with either wildtype or mutant SMO. This combination was also active in cells harbouring all of the known SMO resistant mutations and in cells overexpressing GLI2. 133 In summary, the development of HH-pathway inhibitors will benefit from advances in several research areas: the identification of more-informative biomarkers; rational, mechanism-based therapeutic combinations capable of addressing parallel or compensatory non canonical signalling; and the development of more-effective next-generation agents, encompassing the repurposing of known drugs and compounds that inhibit the pathway through mechanisms distinct from that of cyclopamine to new indications.
Targeting the Wnt pathway
Wnt signalling
The Wnt-signalling cascade comprises three major pathways: the canonical Wnt pathway, which involves activation of β-catenin-T-cell-specific transcription factor (TCF)-lymphoid enhancer-binding factor (LEF) transactivation complex and is implicated in tumorigenesis; the noncanonical planar-cell polarity pathway, which regulates the cytoskeleton; and the noncanonical Wntcalcium pathway, which regulates intracellular calcium levels. 134 Of these pathways, canonical Wnt signalling is the best understood and its inhibition has been the focus of intensive research in cancer and other diseases. Indeed, along with the Notch and HH pathways, suppression of Wnt signalling has led to the development of agents that hold promise to interfere with c arcinogenesis, tumour invasiveness and m etastasis (Figure 3 ).
The prototype Wnt ligand is a lipid-modified secretory glycoprotein of 350-400 amino acids; to date, at least 19 Wnt ligands have been identified in humans. Wnt proteins undergo two types of lipid post-translational modifications that are necessary for secretion: the addition Nature Reviews | Clinical Oncology , mediated by phospho-Dvl, which enables β-catenin to influence gene-expression patterns that determine cell differentiation. Small molecules that stabilize the multiprotein destruction complex and, thus, promote β-catenin degradation, such as tankyrase inhibitors, are in preclinical development. PRI-724 is an investigational agent to disrupt β-catenin-CBP complex, which might shift the balance from β-catenin-mediated gene-expression patterns that block differentiation (and thus promote cell 'stemness') to those that promote differentiation, is currently undergoing testing in clinical trials. Abbreviations: APC, adenomatous polyposis coli protein; BCL9, B-cell lymphoma 9; CBP, cyclic AMP response element-binding protein; CK1, casein kinase 1; DKKs, dickkopfs; Dvl, Dishevelled; Fz, Frizzled; GSK3β, glycogen synthase kinase 3β; LRP5/6, low-density lipoprotein receptor-related protein 5/6; mAbs, monoclonal antibodies; PPARG, peroxisome proliferator-activated receptor γ; Pygo, Pygopus; sFRP, secreted Frizzled-related protein; TCF/LEF, T-cell-specific transcription factor/lymphoid enhancer-binding factor; WIF-1, Wnt inhibitory factor 1. ◀ REVIEWS of palmitate moiety to cysteine residues, 135 and serine palmitoylation by Porcupine in the endoplasmic reticulum ( Figure 3) . 136, 137 After they are secreted from the cell, Wnt ligands bind to a receptor complex consisting of the primary receptor Frizzled (Fz), a member of the G-protein-coupled receptor family, and a co-receptor, lowdensity lipoprotein receptor-related protein 5/6 (LRP5/6). The interaction of Wnt proteins with their receptors can be inhibited by binding of the ligands to endogenous antagonists, including the secreted Frizzled-related-proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). 138, 139 Wnt signalling is also regulated by inhibition of the LRP coreceptors by Dickkopf-related proteins (DKK). 140 When ligand binding and receptor activation is achieved, a signal is propagated via the segment polarity protein dishevelled homologue (Dvl) phosphoprotein, which is located in the cytoplasm. 141 Activated Dvl inhibits Axin-mediated β-catenin phosphorylation, resulting in accumulation of cytoplasmic β-catenin; 142 in the absence of Wnt signalling, a multiprotein destruction complex composed the of the scaffold protein axin, adenomatous polyposis coli (APC), and glycogen synthase kinase 3β (GSK3β) targets cytoplasmic β-catenin for ubiquitination and proteasomal degradation. 143 In the presence of active Wnt signalling, the accumulation of β-catenin enables its translocation to the nucleus, where it induces cellular responses via transactivation of target genes in c onjunction with TCF-LEF t ranscription factors. 144 In several types of malignancy, preclinical data suggests that Wnt signalling contributes to the maintenance of the CSC population. 145 One example is non-melanoma cutaneous tumour stem cells, which are maintained by Wnt-β-catenin signalling in murine models, and potentially in humans. 146 Additionally, Wnt-β-catenin signalling seems to have a role in EMT. 147 In turn, EMT might promote the induction of a CSC phenotype. 2 Thus, targeting Wnt signalling in various cancers might represent a beneficial therapeutic approach.
Agents targeting the Wnt pathway in cancer
Several types of Wnt-signalling inhibitors are under ongoing development as anticancer therapies. For convenience, we divide these agents into three categories: agents approved by the FDA for other indications before their recognition as the Wnt-pathway inhibitors; agents in preclinical development, and investigational agents in clinical studies.
Approved agents
Two nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to inhibit Wnt signalling: sulindac targets Dvl, 148 and is currently being investigated in phase II trials in oncology; celecoxib inhibits β-catenin signalling by cyclo-oxygenase (COX)-dependent and COX-independent mechanisms, 149 and has demonstrated antineoplastic activity in CRC cells. 150 In addition, thiazolidinedione antidiabetic agents (glitazones) cause reverse β-catenin translocation to the plasma membrane, 151 although further investigation of their potential anticancer activity is necessary.
Preclinical investigational agents XAV-939, JW 55, G007-LK, G244-LM, WIKI4 and IWR-1 have been shown to stabilize axin by inhibiting tankyrase, a poly(ADP-ribose) transferase that targets axin for proteosomal degradation. [152] [153] [154] This stabilization of axin, and thus the APC-axin-GSK3β destruction complex, results in degradation of β-catenin (Figure 3 ). Multiple non-NSAID inhibitors of Dvl, have also been developed; for example, NSC668036, 3289-8625, PCN-N3 and FJ9. 155, 156 Specifically, these agents decrease the interaction between Fz and Dvl at the membrane, and this inhibition of Dvl activation stabilizes the destruction complex, promoting β-catenin degradation. In addition, AV65 and artifi cial F-box are agents that have preclinical a ntineoplastic activity via a similar mechanism.
157,158
Agents under clinical investigation ICG-001 and the second-generation compound PRI-724, suppress the interaction of β-catenin with co-activator cyclic AMP response binding protein (CREB) binding protein (CBP or CREBBP) decreasing CBP-dependent gene expression. 159, 160 In a phase Ia study, 159 18 patients were treated with PRI-724 (dose escalation from 40-1,280 mg/m 2 per day) via continuous infusion for 7 days. The compound had an acceptable toxicity profile, with only one grade 3 dose-limiting toxicity event: reversible hyper bilirubinaemia. 159 In this trial, downregulation of survivin (BIRC5) expression in circulating tumour cells was correlated with increasing plasma drug concentrations, implicating this factor as a potential pharmacodynamic biomarker. PRI-724 is currently being evaluated in combination with a modified FOLFOX6 regimen for patients with refractory CRC, with gemcitabine in a phase Ib trial in patients with refractory pancreatic cancer, and a phase Ib/IIa trial for haematological malignancies (Table 3) . [161] [162] [163] In addition to these agents targeting β-catenin, a drug has been developed that inhibits Porcupine and thereby reduces the processing and secretion of Wnt proteins. Currently, this agent, known as LGK-974, is being tested in phase I trials in Wnt-liganddependent tumours-melanoma, breast cancer, and p ancreatic cancer (Table 3) . 164 Two major types of mAbs directed at inhibiting Wnt signalling are also under clinical investigation: those that neutralize Wnt ligands, and those that inhibit the Wnt receptors Fz and LRP. An example of the first drug class is a Wnt3A-neutralizing mAb that had antiproliferative and pro-apoptotic effects in a mouse model of prostate cancer. 165 Furthermore, an anti-Fz10 radiolabelled mAb is being evaluated in a phase I trial for the treatment of synovial sarcoma (Table 3) . Vantictumab (OMP-18R5), [166] [167] [168] [169] [170] [171] a mAb that blocks five Fz receptors (Fz1, Fz2, Fz5, Fz7 and Fz8), and a fusion protein decoy receptor (truncated Fz8), OMP-54F28, [172] [173] [174] are also under investigation in phase I studies in advanced-stage solid tumours (Table 3) . It has been shown that OMP-54F28 inhibits patient-derived xenograft tumour growth and, in particular, decreases CSC numbers. 175 In a phase I dose-escalation clinical trial, 176 OMP-54F28 was well tolerated and six of 25 patients experi enced stable disease responses; two patients with desmoid tumours had prolonged stable disease for >6 months. 176 In summary, investigational agents targeting the Wnt-signalling pathway are all currently in early clinical trials. 166, 167 As more targets within the Wnt pathway are discovered and the existing targets become better understood, novel agents will undoubtedly be developed for clinical testing. Given the critical role of Wnt signalling in CSCs, agents targeting Wnt could potentially achieve antitumour effects that conventional chemotherapy has been unable to reach.
Crosstalk between signalling pathways
During embryogenesis, developmental pathways operate in coordination. Unsurprisingly, therefore, instances of crosstalk among Notch, HH, Wnt, and other signalling pathways have been reported in a variety of cell types. 177 Crosstalk between signalling pathways has the potential to profoundly add to the complexity of cellular responses to external stimuli and poses challenges for investigational drugs.
Interacting developmental signalling pathways
The crosstalk between developmental signalling pathways active in CSCs might offer the opportunity to inhibit multiple cascades by directly targeting only one. For example, preclinical studies have indicated that the GSI Notch-pathway inhibitor PF-03084014 can also inhibit the Wnt pathway by decreasing active β-catenin levels posttranslationally. Specifically, Kwon et al. 178 demonstrated a direct interaction between membrane-associated Notch and β-catenin, which promoted Numb-mediated lysosomal degradation of both Notch and β-catenin; thus, by promoting accumulation of uncleaved Notch in the cell membrane, PF-03084014 indirectly promoted β-catenin degradation. Also, β-catenin can drive activation of Notch signalling by increasing expression of the JAG1 gene, which encodes the Notch ligand Jagged1. 75, 179 These findings suggest that Notch inhibitors, including GSIs, could block β-catenin mediated tumorigenesis, and vice versa. Interestingly, preclinical data shows that PF-03084014-responsive tumours have elevated baseline expression levels of Notch and Wnt pathway genes, 180 supporting the importance of crosstalk between these pathways in tumorigenesis. Furthermore, PF-03084014 inhibited both Notch and Wnt pathways, resulting in a reduction in tumour growth in a CRC xenograft model. 180 Crosstalk between Notch and Wnt signalling might also explain why desmoid tumours often respond to Notch-pathway inhibition, irrespective of whether β-catenin accumulation occurs by CTNNB1 somatic gain-of-function mutation, or by APC loss-offunction in a setting of familial adenomatous polyposis. 181 Of note, a phase I trial of PF-03084014 reported that four of nine evaluable patients with desmoid tumours experienced partial responses and the remaining five patients had some evidence of tumour shrinkage with prolonged disease stabilization. 182 Moreover, the Notch and HH pathways are simultaneously activated in desmoid tumours, as well as desmoid-derived mesencyhmal cell lines. 183 Thus, desmoid tumours are an example of neoplasms in which all three 'CSC pathways' are simultaneously activated, opening the possibility that these tumours could respond to inhibitors of these pathways alone or in combination.
An important consideration regarding the effect of inhibiting one (or more) of these CSC pathways is the potential therapeutic escape through compensatory upregulation of an interconnected pathway. For instance, prolonged, systemic inhibition of Notch signalling can result in HH-pathway activation in the skin as a compensatory phenomenon. 184 This effect might explain why loss of Notch function has been associated with an increased risk of non-melanoma skin cancer development, as reported in patients with Alzheimer disease who were treated with a GSI to block β-amyloid production; in a phase III trial of the GSI semagacestat (GSI450139) in patients with Alzheimer disease, the incidence of non-melanoma skin cancers was 2% in the placebo cohort versus 10-11% in the GSI group. 184 Crosstalk can also occur between the Wnt and HH pathways, through a mechanism involving the endogenous Wnt-inhibitory factor sFRP-1, which is induced by the HH pathway transcription factor GLI1 in gastric cancer cell lines. 185 Specifically, HH signalling was found to inhibit Wnt signalling via upregulation of sFRP-1, 185 and to suppress β-catenin transcriptional activity. 186 Furthermore, HH signalling can induce the Notch ligand Jagged2, at least in some models. 187 These findings suggests that HH-pathway inhibitors might, at least in some cases, inhibit Jagged2-mediated Notch signalling, but may also trigger a compensatory increase in Wnt signalling.
To reduce the potential for CSCs to escape inhibition of individual stem-cell signalling pathways involved in embryonic development that are frequently activated in cancer cells, efforts have been made to target multiple pathways through combination therapy approaches. Indeed, phase I and phase Ib/II trials combining vismodegib to target the HH pathway and the GSI RO4929097 to inhibit Notch signalling have been conducted in patients with breast cancer and sarcoma, respectively (Table 1 and  Table 2) . 69, 188 This combination approach is based on the following rationales: first, the HH and Notch pathways are often active concomitantly in BCCs and medulloblastomas that arise in Ptch-deficient mice and human soft-tissue sarcomas; 189 second, HH signalling leads to transactivation of the Notch-target gene HES1 in a Notch-independent manner, 190 and a negative regulator of Notch signalling, Numb, also suppresses the HH transcription factor GLI1 by targeting it for degradation; 191 third, preclinical investigations in a prostate cancer model showed that combined inhibition of Notch and HH signalling was necessary to deplete the CSC subpopulation of tumour cells. 192 Unfortunately, these combination trials in sarcoma and breast cancer were halted due to pharmacokinetic issues encountered during the development of RO4929097. At present, correlative studies on CSC inhibition are underway to confirm mechanisms of action and/or to identify downstream-target effects by molecular analysis.
Broader signalling crosstalk
Crosstalk between BCR-ABL kinase and Wnt signalling has been recognized in chronic myeloid leukaemia (CML): BCR-ABL kinase stabilizes β-catenin via tyrosine phosphorylation, which enables β-catenin to escape from binding to the axin-APC-GSK3β complex and, therefore, from degradation. 193 Owing to this crosstalk, imatinib is able to decrease β-catenin accumulation by inhibiting BCR-ABL kinase, 193 which might at least partially explain the activity of imatinib in desmoid tumours. Interaction between KIT and β-catenin has also been reported. In particular, β-catenin levels in CSCs isolated from ovarian cancers decreased when KIT was inhibited, indicating that KIT regu lates β-catenin. 194 Furthermore, ABC transporters, such as ABCG2, are known transcriptional targets of β-catenin and are involved in efflux of xenobiotics from cells, and concurrent upregulation of KIT, β-catenin and ABCG2 levels was noted. 194 These findings led to the hypothesis that KIT and/or β-catenin mediate c hemoresistance by i ncreasing expression of ABC transporters. 194 GSK3β, a core component of Wnt signalling through its role in the β-catenin destruction complex, is a serine/ threonine kinase that mediates indirect Wnt-HH crosstalk: GSK3β phosphorylates SMO and GLI1 proteins, leading to their proteasomal degradation. 121 The PI3K-AKT axis inhibits GSK3β and, thus, can concomitantly activate HH and Wnt-β-catenin signalling. 121 In a study of tamoxifen-resistant breast cancer cells, an inhibitor of PI3K-AKT pathway also blocked activation of both HH and Wnt signalling. 121 In addition, GSK3β has been reported to modulate Notch signalling, either positively or negatively depending on the context. GSK3β was demonstrated to phosphorylate and negatively regulate Notch2 195 and the Notch co-activator MAML1. 196 Conversely, GSK3β has been shown to phosphorylate and positively regulate Notch1 in different models. 197 These observations imply that pharmacological inhibition of Wnt or PI3K-AKT has the potential to also modulate Notch and HH, resulting in desirable or undesirable effects. For example, an AKT inhibitor could potentially cause a compensatory increase in Notch activity via GSKβ.
Oestrogen and Notch signalling interact in ER-positive breast cancer cells: oestrogen decreases the activity of Notch1, whereas oestrogen deprivation and tamoxifen cause re-activation of Notch1.
198 Notch1, in turn, can activate ER-dependent transcription in the absence of oestrogen through nuclear inhibitor of nuclear factor κB kinase α (IKKα), 199 thereby promoting endocrine resistance. More recently, Notch4 has been shown to cause endocrine resistance in PKCα-positive, ER-positive breast cancer cells. 46 As might be expected based on these interactions, combinations of anti-oestrogens and Notch inhibitors were highly effective in preclinical models of ER-positive breast cancer, 46, 198 and have shown promise in pilot clinical trials in this disease.
47,48
Conclusions
Targeting CSC via modification of the Wnt, HH and Notch embryonic developmental signalling pathways characteristic of these cells holds the promise of preventing disease relapses. However, developing such agents is fraught with challenges. In particular, more-accurate preclinical models for testing CSC-targeted agents must be developed as the current approaches are not ideal for identifying therapeutics that are likely to be clinically effective. It is now clear that all signalling pathways, including those used by the embryonic 'stem cell' , do not operate in isolation, but function as a coordinated network. The phenotype of tumour cells or CSCs is an output of the entire signalling network. Thus, the develop ment of CSC inhibitors will require a working understanding of key nodes in the stem-cell signalling network. This knowledge, in turn, is propelling the design of mechanism-based combination regimens. Furthermore, informative molecular biomarkers that interrogate pathway activity and predict efficacy are necessary for patient identification and stratification, and as biological correlatives of activity. Moreover, single-agent tumour volume reduction might not be an appropriate end point for CSC agents, owing to therapeutic effects based on interference with rare tumour cell subpopulations; recurrence, progression or survival-based end points, and/or surrogate end points that predict such outcomes, will be more informative. A 'one-size-fits-all' treatment regimen is unlikely to be identified. Rather, systems biology and personalized medicine will enable the design of a range of regimens, which might be useful in different subgroups of patients, or even sequentially in the same patient, adapting treatment to clonal evolution within the tumour. This field remains in its infancy, and like other emerging fields in cancer therapeutics (such as immunotherapy), considerable research effort will be required to yield mature products. However, for the first time in medical history we have the tools to understand cell fate determination in human tumours and target it therapeutically.
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